3-27-2017

PLP and GABA Trigger GabR-mediated Transcription Regulation in Bacillus Subtilis via External Aldimine Formation

Rui Wu
Loyola University Chicago

Ruslan Sanishvili

Boris R. Belitsky
Tufts University

Jose I. Juncosa
Northwestern University

Hoang V. Le
Northwestern University

See next page for additional authors

Recommended Citation
Wu, Rui; Sanishvili, Ruslan; Belitsky, Boris R.; Juncosa, Jose I.; Le, Hoang V.; Lehrer, Helaina J. S.; Farley, Michael; Silverman, Richard B.; Petsko, Gregory A.; Ringe, Dagmar; and Liu, Dali. PLP and GABA Trigger GabR-mediated Transcription Regulation in Bacillus Subtilis via External Aldimine Formation. Proceedings of the National Academy of Sciences of the United States of America, 114, 15: 3891-3896, 2017. Retrieved from Loyola eCommons, Chemistry: Faculty Publications and Other Works, http://dx.doi.org/10.1073/pnas.1703019114
PLP and GABA trigger GabR-mediated transcription regulation in *Bacillus subtilis* via external aldimine formation

Rui Wu,a,1 Ruslan Sanishvili,b Boris R. Belitskyf, Jose I. Juncosa,de Hoang V. Le,a,e,2 Helaina J. S. Lehnerf,g, Michael Farleyg, Richard B. Silvermana,4 Gregory A. Petsko,q,g,4 Dagmar Ringe1, and Dali Liu2,a

The *Bacillus subtilis* protein regulator of the *gabTD* operon and its own gene (*GabR*) is a transcriptional activator that regulates transcription of γ-aminobutyric acid aminotransferase (GABA-AT; GabT) upon interactions with pyridoxal-5′-phosphate (PLP) and GABA, and thereby promotes the biosynthesis of glutamate from GABA. We show here that the external aldimine formed between PLP and GABA is apparently responsible for triggering the GabR-mediated transcription activation. Details of the “active site” in the structure of the GabR effector-binding/oligomerization (Eb/O) domain suggest that binding a monocarboxylate γ-aminoc acid such as GABA should be preferred over dicarboxylic acid ligands. A reactive GABA analog, (S)-4-amino-5-fluoropentanoic acid (AFPA), was used as a molecular probe to examine the reactivity of PLP in both GabR and a homologous aspartate aminotransferase (Asp-AT) from *Escherichia coli* as a control. A comparison between the structures of the Eb/O–PLP–AFPA complex and Asp-AT–PLP–AFPA complex revealed that GabR is incapable of facilitating further steps of the transamination reaction after the formation of the external aldimine. Results of in vitro and in vivo assays using full-length GabR support the conclusion that AFPA is an agonistic ligand capable of triggering GabR-mediated transcription activation via formation of an external aldimine with PLP.

Bacterial transcription regulators are often directly responsive to the changes in metabolite concentrations (1, 2). The regulator of the *gabTD* operon and its own gene (*GabR*) responds to the increase of γ-aminobutyric acid (GABA) concentration in bacterial cells (3) and up-regulates glutamate regeneration from GABA. Belonging to the *Rhizobium melliloti* rhizopine catabolism regulator (MocR)/GabR subfamily in the repressor of the *Bacillus subtilis* glucurate operon (GntR) family of bacterial transcription regulators (2–5), GabR-type regulators characteristically have a large C-terminal effector-binding/oligomerization (Eb/O) domain, which is homologous to the type I aminotransferases (6), and a small N-terminal “winged-helix–turn–helix” (wHTH) DNA-binding domain (7). In *B. subtilis*, GabR represses its own transcription (3, 8). With both pyridoxal-5′-phosphate (PLP) and GABA bound, GabR activates the transcription of two genes, gabT and gabD, that encode the enzymes GABA aminotransferase (GABA-AT) and succinic semialdehyde (SSA) dehydrogenase, respectively, forming a pathway for glutamate regeneration from GABA (3, 8).

Previously, we have reported the crystal structures of full-length GabR as a “head-to-tail” dimer (9), in which electron density supported the existence of PLP bound to K312 of the Eb/O domain in the form of an internal aldimine. Although the PLP-binding site of GabR is largely conserved compared with the PLP-binding site of type I aminotransferases, no aminotransferase activity has been detected for GabR (9). To our knowledge, the existence of PLP in MocR/GabR-type transcription regulators is the only case known in nature where PLP functions as an effector in transcription regulation, including other reports of the MocR/GabR-type regulators DdlR, PdxR, and TauR (10–15). A previous report on GabR has shown that this second metabolite pair of pyridoxamine-5′-phosphate (PMP) and SSA could also cause transcription activation upon binding to GabR (8). In fact, the first half of the “Ping-Pong” transamination catalyzed by GABA-AT (Scheme 1 and Scheme S1) converts PLP and GABA to PMP and SSA reversibly (16). It was

Significance

Regulator of the *gabTD* operon and its own gene (*GabR*) is an intriguing case of molecular evolution, displaying the evolutionary lineage between a pyridoxal-5′-phosphate (PLP)-dependent aminotransferase and a regulation domain of a transcription regulator. Here, PLP’s native function is not a catalytic coenzyme, but an effector of transcription regulation. The chemical species of GabR–PLP–GABA, which is responsible for GabR-mediated transcription activation, has been revealed as a stable external aldimine formed between PLP and GABA by a crystal structure with further support from results in mechanistic crystallography, NMR spectroscopy, and biological assays using both GABA and a GABA analog, (S)-4-amino-5-fluoropentanoic acid (AFPA), as a molecular probe. Our results provide mechanistic insights for a currently understudied *Rhizobium melliloti* rhizopine catabolism regulator (MocR)/GabR subfamily of bacterial transcription regulators.


Reviewers: K.L.K., Otago; and M.T., University of California, Davis. The authors declare no conflict of interest.

Data deposition: The atomic coordinates and structure factors have been deposited in the Protein Data Bank, www.pdb.org (PDB ID codes 5T4J, 5T4K, and 5T4L).

Present address: Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY 10065.

Present address: Department of BioMolecular Sciences, the University of Mississippi School of Pharmacy, University, MS 38677.

Present address: Department of Biochemistry and Molecular Biophysics, Columbia University Medical Center, New York, NY 10032.

To whom correspondence may be addressed. Email: diliu@luc.edu or gpetsko@med.cornell.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1703019114/-/DCSupplemental.

www.pnas.org/cgi/doi/10.1073/pnas.1703019114

PNAS | April 11, 2017 | vol. 114 | no. 15 | 3891–3896
All proteins, including the effector mechanism is shown in the solid box. Head-to-tail dimers of the full-length GabR (PDB ID code 4N0B), GabR effectors and the GABA-AT reaction that is under GabR-mediated regulation are illustrated. The effectors for GabR-mediated transcription activation are shown in dashed boxes. The GABA-AT reaction in a “Ping-Pong” mechanism is shown in the solid box.

Results and Discussion

Protein Purification. All proteins, including *Escherichia coli* aspartate aminotransferase (Asp-AT), were expressed and purified with supplemented PLP (~1 mM), giving a yellow color resulting from the internal aldimine formed between PLP and a conserved lysine.

**Crystallography of GabR Eb/O Domain and Asp-AT Complexed with Ligands.** Crystallization of full-length GabR in the presence of PLP was reported as 2.6 mM. Using X-ray crystallography, NMR spectroscopy, and biological assays, an external aldimine species is reported here that is formed between PLP and GABA when both are bound to the effector-binding site of GabR and is apparently responsible for triggering GabR-mediated transcription activation.

**Schiff Base Formation Between PLP and GABA.** In the Eb/O domain of GabR, the Eb/O domains are in red, the flexible linker regions are in orange, and the DNA-binding domains are in blue. In the Eb/O–PLP–GABA dimeric structures of the GabR Eb/O domain in complexes with GABA (magenta) and AFPA (green). (C) Dimeric structure of *E. coli* Asp-AT (PDB ID code 15FF, cyan).

**Details of the Effector Binding Site in the GabR Eb/O Domain and Schiff Base Formation Between PLP and GABA.** In the effector-binding pocket of the Eb/O domain, the omit map difference electron density (Fo-Fc) revealed the existence of a Schiff base formed between PLP and GABA (Fig. 2A). The ligands are refined with occupancies of 1 in each effector-binding site, indicating a stoichiometry of 1 for each monomer. Two basic residues, R207 and R430, along with H114 from the same subunit, interact with the carboxylate of the GABA moiety. In the previously published structure of the GABA-AT–PLP–aminoxyacetate (AOA) complex (Fig. 2B), the PLP-AOA adduct mimics the PLP-GABA external aldimine, whose carboxylate interacts with one of the conserved arginine residues (R141) (19). Compared with the homologous type 1 aminotransferases, such as GABA-AT (Fig. 2B), GabR is missing one (R141 in GABA-AT) of the two conserved arginines, which are involved in binding to dicarboxylic acid substrates (19, 20), such as l-glutamate or 2-ketoglutarate, in the second half of a typical transamination reaction (Scheme 1). This observed structural difference suggests that GabR has evolved to recognize monocarboxylic acids, such as GABA, preferentially and to orient the ligand in favor of forming a Schiff base with PLP.

Interestingly, the conserved basic residues in GabR are not aligned with GABA-AT residue R141, which had been proposed to interact with the GABA carboxylate (19, 21). Although the AOA-PLP adduct, which mimics the GABA-PLP in the *E. coli* GABA-AT structure, binds to the active site in an anti-conformation, the PLP-GABA Schiff base in GabR is in a gauche conformation (Fig. 3). The dihedral torsional angle of C2-C1-O-N in the PLP-AOA “structural mimic” is measured to be 157° (23° off from an ideal anticonformation) in UCSF Chimera. In the Eb/O–PLP–GABA complex structure (Fig. 3A), the dihedral torsional angle of Cα-Cβ-Cγ-Cδ in the PLP-GABA Schiff base was measured to be 77.3° (17.3° off from an ideal gauche conformation) in UCSF Chimera. Compared with the anti-conformation, the gauche conformation is of higher energy and a relatively minor conformation for GABA molecules in an aqueous environment in the cell.

In all PLP-dependent enzymes, a conserved lysine forms an internal aldimine with PLP in its resting form and acts as a key

**Scheme 1.** GabR effectors and the GABA-AT reaction that is under GabR-mediated regulation are illustrated. The effectors for GabR-mediated transcription activation are shown in dashed boxes. The GABA-AT reaction in a “Ping-Pong” mechanism is shown in the solid box.
catalytic residue during catalytic reactions, as shown in the half of the “Ping-Pong” transamination (6) (Scheme S1). The conserved K312 (9) (Fig. 4) was previously proven to be essential for GabR’s function, although the catalytic capacity to facilitate transamination has never been detected for GabR (8). In the Eb/ O–PLP–GABA complex structure (Fig. 2A), Y281 is observed to block K312 from accessing the PLP–GABA Schiff base, preventing reformation of the internal aldime as well as further transamination-like catalysis, in which the freed catalytic lysine would deprotoxinate the carbon adjacent to the nitrogen atom of the GABA–PLP adduct (19, 22) (Scheme S1). As a result, GabR is unlikely to catalyze the first half of the transamination reaction shown in Scheme 1. As we previously reported (9), in the absence of GABA, Y281 is found in a different orientation, allowing internal aldime formation (Fig. 4). The observed obstruction by Y281 supersedes the previous speculation that GabR’s inability to stabilize the external aldime might be the reason for the lack of observed transaminase activity (9).

**External Aldimine as the Final State of GabR-Mediated Reaction.** The Eb/O–PLP–GABA complex structure at 2.23 Å resolution could not allow us to distinguish between external aldime and ketimine (Scheme S1) for the chemical identity of the PLP–GABA Schiff base observed. Therefore, we used a mechanism-based inactivator, AFPA, which was designed to inactivate PLP-dependent aminotransferases irreversibly (23), as a molecular probe. A previously proposed inactivation mechanism of an aminotransferase, mammalian GABA-AT, by AFPA is shown in Scheme 2. Once a typical aminotransferase reaction progresses beyond the external aldime 1 stage, the AFPA moiety releases the fluoride ion, resulting in a reactive intermediate. Eventually, AFPA inactivates the PLP-dependent aminotransferase via a ternary adduct, in which the AFPA moiety is covalently linked to both PLP and the catalytic lysine, or alternatively forms external aldime 3. The catalytic lysine freed after the formation of the external aldime 1 plays a critical role in assisting the irreversible inactivation of the PLP-dependent enzyme. The formation of the proposed ternary adduct should provide evidence that the reaction between AFPA and PLP can progress beyond the external aldime 1, reaching quinonoid or ketimine intermediates (Scheme 2 and Scheme S1). In contrast, the intact fluorine group of AFPA should indicate that the reaction could not proceed beyond the formation of the external aldime 1. Due to the overall desirable crystallographic behavior of *E. coli* Asp-AT, we chose it as a control for the cocryrstallization experiment with AFPA. *E. coli* Asp-AT, a homolog of the GabR Eb/O domain, has previously been used successfully as a model enzyme to study mechanism-based inactivators of PLP-dependent enzymes (24–26).

Both the GabR Eb/O domain and Asp-AT were cocryrstallized with PLP and AFPA. The structure of the Eb/O–PLP–AFPA complex (refined at 2.25 Å resolution) confirms the formation of an external aldime with the fluoride atom intact in the final adduct (Fig. 5A). To validate the existence of the fluoride atom, extra rounds of refinement were done after deletion of the fluoride atom; the omit map difference electron density (Fo-Fc) strongly supports the presence of the fluoride atom in the complex. Residue Y281 is observed to be in the same position as in the Eb/O–PLP–GABA complex structure (Fig. 4), preventing the access of K312 to the PLP–AFPA Schiff base, which could otherwise potentially push the reaction further along the proposed inactivation pathway (Scheme 2).

This electron density could also be fitted with another atom, so additional validation was used to establish its identity. It is chemically plausible that a hydroxyl or water could react with the reactive intermediate and replace the eliminated fluoride group; the resulting adduct 3 would be structurally similar to the external aldime proposed here (adduct 1 in Scheme 2). At the 2.25 Å resolution obtained for the Eb/O–PLP–AFPA complex structure, it is impossible to distinguish adduct 3 from adduct 1 even with the omit map difference electron density (Fo-Fc) validation shown (as green mesh) in Fig. 5A. Pathway b in Scheme 2 was developed and adduct 3 have never previously been proven in studies of AFPA inactivation. Nevertheless, the AFPA-treated protein sample was subjected to fluorine NMR spectroscopy to eliminate the possibility of an alternative adduct (adduct 3 in Scheme 2, via pathway b in Scheme 2). The results are shown in Fig. S1A. Fig. S1A is the fluorine NMR spectrum that shows a triplet of doublets (J = 25.3 Hz, J = 21.4 Hz), because the fluoride atom is split by its two neighboring hydrogen atoms and then split again by another hydrogen atom on the adjacent carbon in the external aldime form. *Fig. S1B* represents the proton-decoupled fluorine NMR spectrum that shows a singlet, because the fluoride atom and the protons are decoupled. As concluded, the fluoride atom remains intact in the same environment as intact AFPA, even after treatment with a saturated amount of GabR protein.

As a positive control, the structure of the Asp-AT–PLP–AFPA complex (refined at 1.53 Å resolution) showed that the proposed tertiary adduct 2 has formed via pathway a in Scheme 2 (Fig. 5B), indicating that the catalytic actions of the conserved lysine have occurred in Asp-AT but not in the GabR Eb/O domain. On the basis of structural information and NMR results, it was

**Fig. 3.** GABA moiety displays a Gauche conformation. (A) GABA bound in the Eb/O domain is in a gauche conformation. The PLP–GABA external aldime is shown in stick and ball form. The C5 atom is placed (hidden) behind the C6 atom, in the same orientation as the Newman projection for the dihedral torsional angle Cs-C5-C6-N in PLP–GABA, shown in the gauche conformation. (B) AOA–PLP (amine bound in *E. coli* GABA-AT (PDB ID code 1SFF) mimicking the PLP–GABA Schiff base is shown in ball and stick form. The O atom is placed (hidden) behind the C1 atom in the same orientation as the Newman projection for the dihedral torsional angle C2-C1-O-N in PLP–AOA, shown in the anti-configuration.
concluded that the external aldimine 1 is the final chemical species when both PLP and AFPA are bound to the GabR Eb/O domain. The obtained results using AFPA as a molecular probe suggest that the observed Schiff base in the Eb/O–PLP–GABA complex structure is also an external aldimine.

For aminotransferases in general, the external aldimine intermediate can be transiently observed spectroscopically (27). However, mutation of a catalytic residue (28) or chemical modification of the ligands, such as the amino acid (19) or PLP (29, 30), was required to trap a stable external aldimine in an aminotransferase. GabR is a protein reported to be capable of forming a stable external aldimine between PLP and GABA for its function in transcription regulation. Our results are consistent with the ability of another group to detect the external aldimine using spectroscopic approaches (17). Spectroscopic changes, consistent with the formation of external aldimine, were also reported for DdlR (11). Only mild global conformational changes are introduced in the PLP-bound Eb/O domain of GabR upon binding to GABA and formation of the external aldimine. A least squares structural comparison revealed that the Eb/O domains of the GabR–PLP dimer (PDB ID code 4N0B) aligned well with the Eb/O domains of the Eb/O–PLP–GABA complex or the Eb/O–PLP–AFPA complex, with rmsd values for Ca atoms around 1.12 Å and 1.13 Å, respectively. Conformational changes could be more pronounced in the linker region between the Eb/O and wHTH domains, and within the wHTH domains in the full-length dimeric GabR; these conformational changes likely contribute to the triggering of transcription activation.

Functional Significance of External Aldimine Formation. To extrapolate the functional interpretation from the GabR Eb/O domain to the full-length GabR, both in vivo and in vitro assays were conducted to compare the biological effects of GABA and AFPA. When examining GabR-mediated activation in vivo using a gabT/lacZ fusion (3) (Fig. 6D), both GABA and AFPA triggered GabR-mediated transcription activation in B. subtilis cells. The time course of transcription activation was measured and plotted as the calculated Miller units over a 450-min period after addition of the effectors (Fig. 6 A and B). The growth of the culture was also plotted at the same time points as the Miller unit measurements (Fig. 6C). The results clearly demonstrate that both AFPA and GABA cause transcription activation at 200 min and beyond. Although the culture grew better after 300 min in the presence of GABA than it did in the presence of AFPA, the gene activation level was actually more pronounced for AFPA than for GABA after 300 min.

In vitro, GabR, PLP, RNA polymerase, and the gabT promoter-containing DNA fragments were mixed with radioactively labeled nucleotides as described previously (8). The gabT transcripts, which are indicated as the appearance of the newly synthesized 32P-labeled bands, were formed upon addition of either GABA or AFPA (Fig. 6D) proportional to the amount of the effector added. AFPA triggered the GabR-mediated transcription activation in vitro with a higher potency than did GABA. The GabR–PLP–AFPA complex may be a better transcriptional activator than the GabR–PLP–GABA complex. This interpretation could explain the long-lasting activation effect caused by AFPA shown in the in vivo experiments after 300 min (Fig. 6 A–C). Overall, we conclude that AFPA activates the transcription of the gabT promoter via the same chemical principle, which is the formation of the external aldimine, as GABA does in B. subtilis. The activation of transcription by GabR induced by GABA has also been reported in Bacillus thuringiensis, indicating that this function is not unique to B. subtilis (31).

Conclusions

Using crystallography, we have shown that PLP bound to the GabR Eb/O domain reacts with the effector GABA to form a stable external aldimine, which apparently triggers the transcription from the gabT promoter in B. subtilis. This conclusion is consistent with the published spectroscopic analysis of GabR (17) and offers an explanation for the previous results that the effector pair of PMP and SSA can also trigger GabR-mediated transcription activation in vitro (8). Through a reverse transamination-like reaction (Scheme S1), SSA and PMP can potentially form a Schiff base, presenting a structure similar to the PLP–GABA external aldimine (8). However, SSA and PMP may not work as an actual effector pair in vivo. With an evolutionarily modified PLP–GABA–binding site, the GabR Eb/O domain is capable of preferentially binding to GABA and forming
an external aldimine. To perform the role of a transcription regulator, GabR employs Y281 to subdue the Eb/O domain’s catalytic potential by stabilizing the external aldimine formed and preventing its further modification.

Materials and Methods

Materials. Chemicals for the assays were purchased from Fisher Scientific and Sigma–Aldrich. Cloning vectors were obtained from Integrated DNA Technologies. E. coli BL21 (DE3) cells were purchased from New England BioLabs. Bacterial growth media and antibiotics were obtained from Fisher Scientific and Sigma–Aldrich. Crystallization screen solutions and other crystallization supplies were purchased from Hampton Research and Emerald Bio. All chemicals were of the highest quality available.

Truncation and Cloning of GabR Eb/O Domain. The sequence coding for the GabR Eb/O domain was amplified by PCR using previously cloned full-length GabR (in pETT vector from Lucigen) as the template (9), the specific oligonucleotides as primers (forward primer designed as GAAGGAGATACTATGATGCGACGAGCGTGGGATA and reverse primer designed as GTGATGTGGGTGATGATGATCCCCGGTAAACGGGATTTT), and Phusion HF DNA polymerase, following the manufacturer’s instructions. The thermocycler program used included an initial denaturation for 120 s at 95 °C; 35 cycles at 95 °C for 30 s, 50 °C for 60 s, and 72 °C for 60 s; and a final extension at 72 °C for 5 min. The PCR product was inserted into a pETT vector for recombinant expression of GabR Eb/O domain protein with a C-terminal His-tag.

Protein Expression and Purification. Full-length GabR protein and i-aspartate aminotransferase from E. coli were expressed and purified as described (8). The GabR Eb/O domain was overexpressed in E. coli and purified using a similar method. Transformed E. coli BL21 (DE3) cells were grown in 1 L of LB supplemented with 50 μg/mL kanamycin at 37 °C and 250 rpm using a MaxQ6000 shaker bath incubator (Thermo Fisher Scientific) until OD600 nm reached ~0.6. Protein expression was induced by the addition of 0.5 mM isopropyl-beta-D-thiogalactopyranoside. Cells were incubated at 25 °C and harvested after 16 h by centrifuging using a JA10 rotor (Beckman) at 4,800 rpm and 4 °C for 10 min. The cell paste was resuspended in the lysis buffer containing 1× PBS and 10 mM imidazole (pH 8.0), followed by sonication. The resulting suspension was centrifuged twice using a JA20 rotor (Beckman) at 16,500 rpm and 4 °C for 20 min, and the soluble fraction was loaded onto a 10-mL His-Trap column (GE Life Sciences) containing Ni2+ and previously equilibrated with lysis buffer. Elution of the retained proteins was achieved with a linear imidazole gradient (25-column volume, 10–485 mM). Fractions containing the truncated EB/O domain were pooled, concentrated to 2 mL, and loaded onto a 16/60 Superdex 200 size exclusion column (GE Life Sciences) that was previously equilibrated with 84% elution buffer. Fractions containing enzyme were pooled, concentrated, and used immediately after exchanging into suitable buffers for crystallization and biological assays. The wild-type Asp-AT was overexpressed and purified with the protocol used by Onuffer and Kirsch (32).

Crystallization of the GabR Eb/O and X-Ray Diffraction Data Collection. After the initial crystallization screen and optimization, the GabR Eb/O domain was crystallized via hanging drop methods at 25 °C. The hanging drops were prepared with 1 μL of 12 mg/mL preincubated protein with inhibitor solution and 1 μL of the reservoir solution that contained 0.1 M Tris (pH 8.5) buffer and 20% ethanol. Crystals were harvested in about 10 d. For cryocooling, crystals were transferred to the reservoir solution with 20% glycerol as a cryoprotectant, and were flash-cooled by plunging in liquid nitrogen. The cocrystallization of Asp-AT and AFPA was conducted according to previous studies (24, 25). Diffraction data were collected at GM/CA@APS beamlines 23ID-B and 23ID-D at the Advanced Photon Source (Argonne National Laboratory). The wavelength used for data collection was 1.0332 Å, and diffraction images were recorded on 4 × 4 tiled CCD detectors (Rayonix) with 300 × 300-mm² sensitive areas. All data were indexed, integrated, scaled, and merged using HKL2000 (33).

Phasing, Model Building, and Refinement. Diffraction data were phased with molecular replacement using the program Phaser (34) in the CCP4 software suite (35). A previously solved full-length GabR structure (9), truncated to contain residues 107–479, was used as the search model. The previously solved Asp-AT model 2Q7W (25) was used as the search model for the E. coli Asp-AT–PLP–AFPA structure. Rigid body refinement followed by restrained refinement was carried out in Refmac (36). Model building was conducted using the program Coot (37). Iterative rounds of model building and re-refinement generated the final coordinates. The external aldimine ligands, PLP-GABA or PLP-AFPA, were removed from the model; the model without a ligand was refined in Phenix using simulated annealing refinement. The starting temperature was 5,000 K, the final temperature was 300 K, and the annealing process was conducted in 50 steps with a cooling rate of 100° per step. The SA OMIT map was then generated after the above refinement.

In Vivo and In Vitro Assays for GabR-Dependent Transcription Activation. The in vivo assay was conducted as previously described (8), using GABA or AFPA as an effector (0.625–20 mM). The expression signal was detected using ONPG (ortho-nitrophenyl-beta-D-galactoside) as a substrate for the beta-galactosidase (lacZ gene product) generating a spectroscopic signal at 420 nm. The time course was measured and plotted over a 200-min period. Each point is the average value of triplicate measurements. For each measurement, the Miller units were calculated using the following equation: Miller Units = (O.D.420)/(O.D.600) × Time × 1.25 × Volume, Volume = 0.8 mL. In vitro GabR-dependent RNA polymerase reactions were performed as previously described (8).

Fig. 5. AFPA as a molecular probe in the Eb/O domain and in Asp-AT (as a control). (A) PLP-AFPA external aldimine is bound to the Eb/O domain. Two sets of simulated annealing electron density omit maps (Fo-Fc) are shown. Both are shown at 3.5 σ. The gray map was generated omitting the complete ligand adducts, confirming the existence of the ligands. The green map was generated omitting only the fluorine atom, confirming the existence of fluorine in AFPA. (B) Electron density omit map of the E. coli Asp-AT–AFPA–PLP complex, generated by omitting AFPA, PLP, and lysine 246 from the calculation. *Indicates that R280 is from a different subunit of the Asp-AT dimer.

Fig. 6. Biological effects of GABA and AFPA. (A) Expression of gabT/lacZ is indicated by calculated Miller units over time. The calculated Miller units of the culture without addition of GABA or AFPA were no higher than 2. (B) Self-developed film indicating the newly synthesized gabT mRNA. (C) Culture growth (indicated with O.D.600 values) while supplemented with GABA or AFPA. (D) Lane 1: control without GABA or AFPA. Lanes 2–7: GABA added at concentrations of 0.625, 1.25, 2.5, 5, 10, and 20 mM, respectively. Lanes 8–13: AFPA added with concentrations of 0.625, 1.25, 2.5, 5, 10, and 20 mM, respectively.
NMR Spectroscopy. The protein (100 mg) was treated with AFPA. The molar ratio of the protein and AFPA was 2:1 to minimize free AFPA in the solution. The sample was concentrated to a volume of 0.4 mL by centrifugation. Deuterium oxide (0.15 mL) was added, and the solution was transferred to a 5-mm standard NMR tube. Fluorine NMR and proton-decoupled fluorine NMR spectra were taken at the Northwestern Integrated Molecular Structure Education and Research Center facility on an Agilent DD2 500-MHz spectrometer with an Agilent 5-mm HFX probe at 26 °C [19F NMR δ 229.87 (td, J1 = 25.3 Hz, J2 = 21.4 Hz), proton-decoupled 19F NMR δ 229.87 (s)].

Structural Analysis and Figure Making. All structural analyses were conducted in Coot (37) and UCSF Chimera (39). Structure comparison of the PLP-amino acid-binding site was conducted in two steps (Figs. 2B and 6). First, the overall structural comparison/overlap was conducted in UCSF Chimera using the Needleman–Wunsch algorithm. Second, manual adjustments were done by overlapping the pyridine ring of the PLP to achieve better pattern matching for the conserved key residues in the PLP/amino acid-binding site for comparison. All structural figures were made in UCSF Chimera.

ACKNOWLEDGMENTS. We thank Dr. Miguel Ballicora for helpful discussions and NIH Grant 1R15GM113229-01 (to D.L.) and Loyola University Chicago (D.L.) for funding. The GM/CA@APS has been funded in whole or in part with federal funds from the National Cancer Institute (Grant ACB-12002) and the National Institute of General Medical Sciences (Grant AGM-12006). R.B.S. is funded by the National Institute on Drug Abuse (Grant DA030804). Use of the Advanced Photon Source was supported by the US Department of Energy, Basic Energy Sciences, Office of Science, under Contract DE-AC02-06CH11357. Support for the NMR spectrometer funding was provided by the International Institute of Nanotechnology.